Stephan Krähenbühl
Stephan Krähenbühl
Clinical Pharmacology & Toxicology, Basel, Switzerland
Patvirtintas el. paštas
Drug-related problems in hospitals: a review of the recent literature
A Krähenbühl-Melcher, R Schlienger, M Lampert, M Haschke, J Drewe, ...
Drug safety 30, 379-407, 2007
Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: meta-analysis of randomized trials
C Stettler, S Allemann, P Jüni, CA Cull, RR Holman, M Egger, ...
American heart journal 152 (1), 27-38, 2006
Long-term metformin use is associated with decreased risk of breast cancer
M Bodmer, C Meier, S Krähenbühl, SS Jick, CR Meier
Diabetes care 33 (6), 1304-1308, 2010
Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis
M Bodmer, C Meier, S KRahenbuhl, SS Jick, CR Meier
Diabetes care 31 (11), 2086-2091, 2008
Fulminant Liver Failure in Association with the Emetic Toxin of Bacillus cereus
H Mahler, A Pasi, JM Kramer, P Schulte, AC Scoging, W Bär, ...
New England Journal of Medicine 336 (16), 1142-1148, 1997
Interaction between grapefruit juice and midazolam in humans
HHT Kupferschmidt, HR Ha, WH Ziegler, PJ Meier, S Krähenbühl
Clinical Pharmacology & Therapeutics 58 (1), 20-28, 1995
Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting enzyme 2 in healthy human subjects
M Haschke, M Schuster, M Poglitsch, H Loibner, M Salzberg, ...
Clinical pharmacokinetics 52, 783-792, 2013
Risk factors for gastrointestinal bleeding: a hospital-based case-control study
P Vonbach, R Reich, F Möll, CR Meier
Swiss medical weekly 137 (4950), 705-710, 2007
The human brain endothelial cell line hCMEC/D3 as a human blood‐brain barrier model for drug transport studies
B Poller, H Gutmann, S Krähenbühl, B Weksler, I Romero, PO Couraud, ...
Journal of neurochemistry 107 (5), 1358-1368, 2008
Toxicity of statins on rat skeletal muscle mitochondria
P Kaufmann, M Török, A Zahno, KM Waldhauser, K Brecht, S Krähenbühl
Cellular and Molecular Life Sciences CMLS 63, 2415-2425, 2006
Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria
S Krähenbühl, C Talos, S Fischer, J Reichen
Hepatology 19 (2), 471-479, 1994
Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man
HHT Kupferschmidt, KE Fattinger, HR Ha, F Follath, S Krähenbühl
British journal of clinical pharmacology 45 (4), 355-359, 1998
Dose adjustment in patients with liver disease
F Delco, L Tchambaz, R Schlienger, J Drewe, S Krähenbühl
Drug safety 28, 529-545, 2005
Tumor targeting using liposomal antineoplastic drugs
J Huwyler, J Drewe, S Krähenbühl
International journal of nanomedicine 3 (1), 21-29, 2008
Mechanisms of benzarone and benzbromarone‐induced hepatic toxicity
P Kaufmann, M Török, A Hänni, P Roberts, R Gasser, S Krähenbühl
Hepatology 41 (4), 925-935, 2005
Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood–brain barrier
B Poller, J Drewe, S Krähenbühl, J Huwyler, H Gutmann
Cellular and molecular neurobiology 30, 63-70, 2010
Bile duct injury and use of cholangiography during laparoscopic cholecystectomy
U Giger, M Ouaissi, SFH Schmitz, S Krähenbühl, L Krähenbühl
Journal of British Surgery 98 (3), 391-396, 2011
Duloxetine Inhibits Effects of MDMA (“Ecstasy") In Vitro and in Humans in a Randomized Placebo-Controlled Laboratory Study
CM Hysek, LD Simmler, VG Nicola, N Vischer, M Donzelli, S Krähenbühl, ...
PloS one 7 (5), e36476, 2012
Evaluation of frequently used drug interaction screening programs
P Vonbach, A Dubied, S Krähenbühl, JH Beer
Pharmacy world & science 30, 367-374, 2008
Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats
S Krähenbühl, C Talos, BH Lauterburg, J Reichen
Hepatology 22 (2), 607-612, 1995
Sistema negali atlikti operacijos. Bandykite vėliau dar kartą.
Straipsniai 1–20